Company: HCTI
Filing Date: 2025-04-22
Form Type: S-1/A
Source: 0001213900-25-034248
Chunk: 14

Company: Healthcare Triangle, Inc.
Filing Date: 2025-04-22
Form: S-1/A
Chunk 14
---
 to this Offering

An active trading market for our shares may not be sustained.

Although our shares are listed on The Nasdaq Stock
Market LLC, the market for our shares has demonstrated varying levels of trading activity. The current level of trading may not be sustained
in the future. The lack of an active market for our shares may impair investors’ ability to sell their shares at the time they wish
to sell them or at a price that they consider reasonable, may reduce the fair market value of their shares and may impair our ability
to raise capital to continue to fund operations by selling shares and may impair our ability to acquire additional intellectual property
assets by using our shares as consideration.

Future sales of substantial amounts of our common stock could adversely affect the market price of our common stock.

We may choose to raise additional capital due
to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans.
If additional capital is raised through the sale of equity or convertible debt securities, or perceptions that those sales could occur,
the issuance of these securities could result in further dilution to investors purchasing our common stock in this offering or result
in downward pressure on the price of our common stock, and our ability to raise capital in the future.

The issuance of shares upon exercise of derivative securities may cause immediate and substantial dilution to our existing stockholders.

The issuance of shares upon exercise of our outstanding
warrants, including the Purchase Warrants may result in substantial dilution to the interests of other stockholders since these selling
stockholders may ultimately convert or exercise and sell all or a portion of the full amount issuable upon exercise. The issuance of these
shares will have the effect of further diluting the proportionate equity interest and voting power of holders of our common stock.

If the Series B Warrants are exercised by way of the “zero exercise price” option, stockholders may suffer substantial dilution.

If the Series B Warrants are exercised by
way of the “zero exercise price” option, such exercising holder will receive 3 shares of Common Stock for each Series B Warrant
they exercise, without any cash payment to us. If a “zero exercise price” option is utilized, such exercise will result in
substantial dilution to stockholders. As a result of this feature, we do not expect to receive any cash proceeds from the exercise of
the Series B Warrants in these circumstances because it is highly unlikely that a Series B Warrant holder will elect to pay an exercise